Pharmaceutical use of heparanase inhibitors in alzheimer's disease

By inhibiting heparinase activity through heparinase inhibitors, protecting the blood-brain barrier, and regulating neuroinflammatory responses, the treatment challenges of Alzheimer's disease have been solved, achieving effective treatment and prevention of Alzheimer's disease.

WO2026233196A1PCT designated stage Publication Date: 2026-11-12UNIVERSITY OF HEALTH & REHABILITATION SCIENCES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/093831
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2026-04-29
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Currently, there are no effective drugs with few side effects for the treatment or prevention of Alzheimer's disease, and the application of heparinase inhibitors in improving Alzheimer's disease has not been fully developed.

Method used

Provides heparanase inhibitors, including trisaccharide and pentasaccharide compounds and their salts or solvates, as well as fondaparinux sodium, which improve Alzheimer's disease symptoms by inhibiting heparanase activity, protecting the blood-brain barrier, regulating neuroinflammatory responses, reducing the accumulation of toxic protein Aβ and phosphorylated Tau protein.

Benefits of technology

It inhibits heparanase activity, reduces damage to glycocalyx structure, protects the blood-brain barrier, improves behavioral performance in Alzheimer's disease model mice, delays cognitive decline, reduces the generation and accumulation of toxic proteins, and improves core clinical symptoms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2026093831_12112026_PF_FP_ABST
    Figure CN2026093831_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides use of heparanase inhibitors, including a trisaccharide compound, a pentasaccharide compound, fondaparinux sodium, etc., in the preparation of drugs for treating or preventing Alzheimer's disease. It has been found that the compounds can improve or inhibit the aggregation of toxic proteins, ameliorate or inhibit inflammation of the central nervous system, and treat Alzheimer's disease.
Need to check novelty before this filing date? Find Prior Art

Description

Pharmaceutical Uses of Heparinase Inhibitors in Alzheimer's Disease

[0001] This application claims priority to an earlier application filed on May 8, 2025, with patent application number 202510587808.2, entitled "Pharmaceutical Use of Heparinase Inhibitors in Alzheimer's Disease". The entire contents of the earlier application are incorporated herein by reference. Technical Field

[0002] This invention belongs to the field of biomedical technology, specifically relating to the application of heparanase inhibitors in the preparation of drugs for the treatment or prevention of Alzheimer's disease. Background Technology

[0003] Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive impairment and behavioral disturbances. Its main pathological features are the accumulation of abnormal toxic proteins such as Aβ and hyperphosphorylated Tau protein in the brain, as well as significant neuronal death. Alzheimer's disease places a heavy burden on families and society. However, there are currently no drugs to prevent or reverse AD; therefore, AD is a pressing global public health problem requiring immediate attention, and there is an urgent need to develop effective treatments with minimal side effects.

[0004] Heparanase (HPA) is an endoglucosidase that specifically degrades heparan sulfate on the cell surface and in the extracellular matrix, disrupting the dense glycocalyx layer and leading to impaired epithelial / endothelial barrier function. This barrier disruption triggers a series of pathological processes, such as inflammatory cell infiltration, increased vascular permeability, and tissue damage, thereby exacerbating the severity of various diseases. Due to its crucial role in disease progression, heparanase has become an important therapeutic target for some diseases, and research on heparanase inhibitors shows potential application value in improving the treatment of these diseases. Summary of the Invention

[0005] The inventors of this application administered the trisaccharide compound, pentasaccharide compound, and fondaparinux sodium of this invention to an AD mouse model, respectively, and found that the compounds could improve the behavior of AD model mice and inhibit the accumulation of toxic protein Aβ and phosphorylated Tau protein in the brain tissue of the model mice, thereby exhibiting therapeutic activity for AD. Further research by the inventors of this application revealed that the trisaccharide compound, pentasaccharide compound, and fondaparinux sodium of this invention all possess HPA inhibitory activity. Mechanistically, they at least achieve the effect of inhibiting the accumulation of toxic protein Aβ and phosphorylated Tau protein, ultimately improving the behavior of AD model mice, by inhibiting HPA activity, reducing damage to the glycocalyx structure, protecting and repairing the blood-brain barrier, and simultaneously regulating the neuroinflammatory response of the central nervous system (especially brain regions related to memory and cognitive function).

[0006] Based on this, the present invention provides the use of HPA inhibitors in the preparation of medicaments for the treatment or prevention of Alzheimer's disease.

[0007] This invention also provides HPA inhibitors for the treatment or prevention of Alzheimer's disease.

[0008] The present invention also provides an HPA inhibitor for the treatment or prevention of Alzheimer's disease.

[0009] The HPA inhibitor may be an inhibitor that inhibits HPA activity or an inhibitor that inhibits the expression level of the HPA protein. The inhibitory activity may be reversible or irreversible.

[0010] The inhibitors that inhibit HPA activity refer to inhibitors that can bind to HPA and block HPA from binding to heparan sulfate, thereby inhibiting the enzymatic hydrolysis of heparan sulfate by HPA. Inhibitors of HPA activity include, but are not limited to, HPA antibodies, peptides that inhibit HPA activity, and small molecule compounds.

[0011] Inhibitors that suppress HPA protein expression levels can be antisense nucleic acid sequences or interfering sequences (such as siRNA, miRNA, shRNA, dsRNA, etc.) of the HPA gene, or peptides or small molecule compounds that can inhibit HPA gene transcription, or peptides or small molecule compounds that can inhibit the translation of HPA mRNA into protein.

[0012] In some embodiments of the present invention, the HPA inhibitor is selected from trisaccharide compounds of formula A or their salts or solvates, pentasaccharide compounds of formula M or their salts or solvates, fondaparinux sodium, etc.

[0013] According to the present invention, in the trisaccharide compound of formula A, the three monosaccharides from left to right are represented by B, C, and D, respectively:

[0014] in:

[0015] R1, R2, R3, and R4 may be the same or different, and are independently selected from H or -SO3H.

[0016] R5 is a -C1-5 alkyl, -C1-5 alkylene-NH2, or -C1-5 alkylene-NHSO3H.

[0017] R6 is -OH, -OSO3H, or -NHSO3H.

[0018] The salt of Formula A is a salt formed with a monovalent cation, a divalent cation, and / or a trivalent cation.

[0019] The monovalent cation is, for example, selected from Na. + K + Li + NH4 + etc.; the divalent cation is selected, for example, from Ca... 2+ Cu 2+ Zn 2+ Fe 2+ Mg 2+ Mn 2+ etc.; the trivalent cation is selected, for example, from Al 3+ Fe 3+ Etc. Those skilled in the art will understand that when the compound forms a salt, the corresponding group in formula A is its anionic group, such as -COO. - 、 -SO3 - .

[0020] The compound of formula A is a compound with a single optical activity, namely Glc(1→4)IdoA(1→4)GlcNS, where the D sugar terminal group is α or β configuration.

[0021] In some embodiments of the present invention, in formula A, R1 is selected from H or -SO3H; R2, R3 and R4 are the same, all of which are H; R6 is -OH, -OSO3H or -NHSO3H.

[0022] In some embodiments of the present invention, in formula A, R1, R2, R3 and R4 are the same, all being H; R6 is -NHSO3H.

[0023] In some other embodiments of the present invention, in formula A, R1 is -SO3H; R2, R3 and R4 are the same, all of which are H; R6 is -OH.

[0024] In some embodiments of the present invention, in formula A, R5 is -C1-3 alkyl, -C2-4 alkylene-NH2, or -C2-4 alkylene-NHSO3H. Preferably, R5 is methyl, ethyl, -C2H4NH2, -C2H4NHSO3H, -C3H6NH2, or -C3H6NHSO3H.

[0025] In some embodiments of the present invention, the salt of formula A is a salt formed with a monovalent cation selected from Na. + K + Li + NH4 + Preferably, the monovalent cation is selected from Na. + K + .

[0026] In some embodiments of the present invention, the salt of formula A is a salt formed with a divalent cation selected from Ca. 2+ Cu 2+ Zn 2+ Fe 2+ Mg 2+ Mn 2+ Preferably, the divalent cation is Ca. 2+ .

[0027] In some embodiments of the present invention, in formula A, R1, R2, R3, and R4 are the same, all being H; R6 is -NHSO3H; R5 is -C1-5 alkyl, -C1-5 alkylene-NH2, or -C1-5 alkylene-NHSO3H, and the salt is a salt formed with a monovalent cation, a divalent cation, and / or a trivalent cation. Preferably, R5 is -C1-3 alkyl, -C2-4 alkylene-NH2, or -C2-4 alkylene-NHSO3H; more preferably, R5 is methyl, ethyl, -C2H4NH2, -C2H4NHSO3H, -C3H6NH2, or -C3H6NHSO3H. Preferably, the salt is a salt formed with a monovalent cation selected from Na. + K + Li + NH4 + Preferably, the monovalent cation is selected from Na. + K + Alternatively, the salt is a salt formed with a divalent cation selected from Ca. 2+ Cu 2+ Zn 2+ Fe 2+ Mg 2+ Mn 2+ Preferably, the divalent cation is Ca. 2+ .

[0028] In some embodiments of the present invention, in formula A, R1 is -SO3H; R2, R3, and R4 are the same, all being H; R6 is -OH; R5 is -C1-5 alkyl, -C1-5 alkylene-NH2, or -C1-5 alkylene-NHSO3H; the salt is a salt formed with a monovalent cation, a divalent cation, and / or a trivalent cation. Preferably, R5 is -C1-3 alkyl, -C2-4 alkylene-NH2, or -C2-4 alkylene-NHSO3H; more preferably, R5 is methyl, ethyl, -C2H4NH2, -C2H4NHSO3H, -C3H6NH2, or -C3H6NHSO3H. Preferably, the salt is a salt formed with a monovalent cation selected from Na. + K + Li + NH4 + Preferably, the monovalent cation is selected from Na. + K + Alternatively, the salt is a salt formed with a divalent cation selected from Ca. 2+ Cu 2+ Zn 2+ Fe 2+ Mg 2+ Mn 2+ Preferably, the divalent cation is Ca. 2+ .

[0029] In one embodiment of the present invention, the structural formula of compound A is as follows, referred to as CV010 in the present invention.

[0030] In one embodiment of the present invention, the sodium salt structure of compound A is as follows, referred to as CV016 in the present invention.

[0031] In another embodiment of the present invention, the structural formula of compound A is as follows, and is referred to as TSC in the present invention.

[0032] In another embodiment of the invention, the sodium salt of compound A has the following structural formula, referred to as TSC19 in this invention.

[0033] The structural formula of the pentasaccharide compound of formula M is as follows, where the five monosaccharides from left to right are represented by G, H, J, K, and L:

[0034] The salt of formula M is a salt formed with a monovalent cation, a divalent cation, and / or a trivalent cation.

[0035] The monovalent cation is, for example, selected from Na. + K + Li + NH4 + etc.; the divalent cation is selected, for example, from Ca... 2+ Cu 2+ Zn 2+ Fe 2+ Mg 2+ Mn 2+ etc.; the trivalent cation is selected, for example, from Al 3+ Fe 3+ Etc. Those skilled in the art will understand that when the compound of formula M forms a salt, the corresponding group in formula M is its anionic group, such as -COO. - 、 -SO3 - .

[0036] In some embodiments of the present invention, the salt is a salt formed with a monovalent cation, wherein the monovalent cation is selected from Na. + K + Li + NH4 + Preferably, the monovalent cation is selected from Na. + K + .

[0037] In some embodiments of the present invention, the salt is a salt formed with a divalent cation selected from Ca. 2+ Cu 2+ Zn 2+ Fe 2+ Mg 2+ Mn 2+ Preferably, the divalent cation is Ca. 2+ .

[0038] The compound of formula M is a compound with a single optical activity, namely GlcNS6S(1→4)GlcA3Sβ(1→4)GlcNS3S6S(1→4)IdoA2S(1→4)GlcNS6S, and the L-sugar terminal methyl ester is in the α configuration.

[0039] In one embodiment of the present invention, the structural formula of formula M is as follows, which is referred to as CV001 in the present invention.

[0040] In one embodiment of the present invention, the sodium salt structure of formula M is as follows, referred to as CV122 in the present invention, which is essentially the sodium salt of CV001.

[0041] In one embodiment of the present invention, the potassium salt structure of formula M is as follows, referred to as CV123 in the present invention, which is essentially the potassium salt of CV001.

[0042] In some embodiments of the above technical solutions of the present invention, the HPA inhibitor is a trisaccharide compound of formula A or its salt or solvate.

[0043] In some embodiments of the above technical solutions of the present invention, the HPA inhibitor is a pentasaccharide compound of formula M or its salt or solvate.

[0044] In some embodiments of the above technical solutions of the present invention, the HPA inhibitor is fondaparinux sodium.

[0045] The prevention or treatment of Alzheimer's disease includes, but is not limited to: delaying cognitive decline and improving the core clinical symptoms of AD, including memory loss, cognitive impairment, aphasia, apraxia, and neuropsychiatric symptoms (such as anxiety, depression, and hallucinations); reducing or inhibiting the production and accumulation of toxic protein Aβ and phosphorylated Tau protein.

[0046] Preparation of compounds:

[0047] According to the present invention, the compound of formula A can be derived from the fully protected trisaccharide intermediate of formula E. The compound is obtained by sequentially removing a hydroxyl protecting group, O-sulfonation, optional azide reduction reaction, and finally N-sulfonation. Those skilled in the art will understand that after obtaining compound A, the corresponding salt can be obtained by salting it with a cation, for example, by exchanging compound A with a cation exchange resin to prepare its corresponding monovalent, divalent, or trivalent salt.

[0048] In the fully protected trisaccharide intermediate E, Rx can be an azide group, an -O-acyl group (including but not limited to chloroacetyl, acetyl, benzoyl, pivaloyl, etc.), or an -O-benzyl group. 11 R 21 R 31 R 41 R 51 and R 61 They can be the same or different, and are independently selected from chloroacetyl, acetyl, benzoyl, pivaloyl, benzyl, and p-methoxybenzyl. In one embodiment, Rx is preferably an azide group, R 11 R 21 R 31 and R 51 Same, R 41 and R 61 Same or different, and both are different from R 11 R 21R 31 and R 51 Further optimization preferred Rx to be an azide group, R 11 R 21 R 31 and R 51 They are the same, both are benzyl, R 41 and R 61 The groups, whether the groups are the same or different, are independently selected from acetyl and benzoyl groups. In another embodiment, Rx is preferably -O-benzyl, and R... 21 R 31 and R 51 Same, R 11 R 41 and R 61 Same or different; further preferred Rx is -O-benzyl, R 21 R 31 and R 51 They are the same, both are benzyl, R 11 R 41 and R 61 Whether the groups are the same or different, they are independently selected from acetyl and benzoyl groups.

[0049] Preferably, in the reaction, all hydroxyl groups to be sulfonated are deprotected in one step, and after the hydroxyl O-sulfonation, all hydroxyl groups not to be sulfonated are deprotected in one step.

[0050] In a specific embodiment of the present invention, the present invention uses the synthesis method described above to synthesize CV010 and CV016: Rx, R 11 R 21 R 31 R 41 R 51 and R 61 The definitions are the same as before, and the reaction pathway is as follows:

[0051] In one specific embodiment of the preparation of CV010 and CV016, R 11 R 21 R 31 and R 51 All are benzyl, R 41 For acetyl, R 61 The radical is benzoyl, and Y is selected from H and Na. + K + Li + NH4 + H or Na are preferred. + .

[0052] CV010 and CV016 can also be prepared by referring to the method described in CN116854752A.

[0053] In another specific embodiment of the present invention, the present invention uses the aforementioned synthesis method to synthesize TSC and TSC19:Rx, R 11 R 21 R 31 R 41 R 51 and R 61 The definitions are the same as before, and the reaction pathway is as follows:

[0054] In one specific embodiment of the preparation of TSC and TSC19, R 21 R 31 and R 51 All are benzyl, R 11 and R on D sugar 41 For acetyl, R 61 and R on β sugar 41 The radical is benzoyl, and Y is selected from H and Na. + K + Li + NH4 + H or Na are preferred. + .

[0055] TSC and TSC19 can also be prepared by referring to the method described in CN119708089A.

[0056] The fully protected trisaccharide intermediate E can be derived from the monosaccharide intermediate F. and disaccharide receptor 4 It is obtained through a glycosylation reaction.

[0057] Rx can be an azide group, an -O-acyl group (including but not limited to chloroacetyl, acetyl, benzoyl, pivaloyl, etc.), or an -O-benzyl group. 11 R 21 R 31 R 41 R 51 and R 61 They may be the same or different, and are independently selected from chloroacetyl, acetyl, benzoyl, pivaloyl, benzyl, and p-methoxybenzyl; X is a leaving group suitable for reacting with other acceptors to form bonds between glycosides.

[0058] Preferably, X is a hydroxyl group, a thioalkyl group, a thioaryl group, a halogen, a trichloroimine acetyl group, a phosphate ester, or a tert-butyldiphenylsilyloxy group.

[0059] Preferably, Rx is an azide group, R 11 R 21 R 31 and R 51 They are the same, both are benzyl, R41 and R 61 Whether the Rx group is the same or different, it is independently selected from acetyl or benzoyl; or, preferably, Rx is -O-benzyl, R 21 R 31 and R 51 They are the same, both are benzyl, R 11 R 41 and R 61 Whether the groups are the same or different, they are independently selected from acetyl and benzoyl groups.

[0060] According to the present invention, the glycosylation reaction temperature is -80°C to -10°C. The reaction can be carried out under strong acid conditions, such as trifluoromethanesulfonic acid, TBSOTf, TMSOTf, etc.

[0061] In one embodiment of the present invention, the fully protected trisaccharide intermediate 1 is obtained by glycosylation of a monosaccharide intermediate 3 and a disaccharide acceptor 4, as shown in the following reaction formula:

[0062] In one embodiment of the present invention, the fully protected trisaccharide intermediate 2 is obtained by glycosylation of monosaccharide intermediate 2-1 and disaccharide acceptor 4, as shown in the following reaction formula:

[0063] The disaccharide intermediate 4 can be obtained from the monosaccharide intermediate 6 and the monosaccharide intermediate 7, as shown in the following reaction formula:

[0064] The monosaccharides 6, 7, and 4 disaccharide receptor used in the above preparation method can be prepared according to synthetic methods known in the art, such as: Preactivation-based, iterative one-pot synthesis of anticoagulant pentasaccharide fondaparinux Sodium. Org. Chem. Front., 2019, 6, 3116; Total Synthesis of Anticoagulant Pentasaccharide Fondaparinux. ChemMedChem, 2014, 9, 1071–1080. The definitions of the functional groups in monosaccharides 6, 7, and 4 are the same as those of the corresponding functional groups described above.

[0065] Therefore, the present invention also provides the intermediates in the above synthesis method and their preparation methods.

[0066] A monosaccharide intermediate 3 has the following structure: Among them, R is preferred. 11 and R 31 All are benzyl, R41 It is chloroacetyl, acetyl, benzoyl, or pivaloyl. In one embodiment of the invention, the monosaccharide intermediate 3 has R... 11 and R 31 All are benzyl, R 41 It is an acetyl group, which can be either α or β configuration, named 3-1, and has the following structural formula:

[0067] The reaction formula for its preparation method is as follows:

[0068] A monosaccharide intermediate 2-1 has the following structure: Among them, R is preferred. 31 It is benzyl, R 11 and R 41 Independently selected from chloroacetyl, acetyl, benzoyl, or pivaloyl. In one embodiment of the invention, the monosaccharide intermediate 2-1, R... 31 It is benzyl, R 11 For acetyl, R 41 It is a benzoyl group, which can be either α-configuration or β-configuration, named F-1, with the structural formula as follows:

[0069] Its preparation method is as follows:

[0070] A disaccharide intermediate 4 has the following structure: Among them, R is preferred. 21 and R 51 It is benzyl, R 41 and R 61 The same or different, selected from chloroacetyl, acetyl, benzoyl, or pivaloyl. In one embodiment of the invention, the R of the disaccharide intermediate 4... 21 and R 51 It is benzyl, R 41 For acetyl, R 61 It is benzoyl, named 4-1, and has the following structural formula:

[0071] Disaccharide intermediate 4-1 can be prepared using synthetic methods known in the art, such as Total Synthesis of Anticoagulant Pentasaccharide Fondaparinux. ChemMedChem, 2014, 9, 1071–1080.

[0072] A fully protected trisaccharide intermediate 1 has the following structural formula:

[0073] Where R11 R 21 R 31 R 41 R 51 and R 61 They may be the same or different, and are independently selected from chloroacetyl, acetyl, benzoyl, pivaloyl, benzyl, and p-methoxybenzyl. In one specific embodiment of the invention, R 11 R 21 R 31 and R 51 All are benzyl, R 41 For acetyl, R 61 It is benzoyl.

[0074] The present invention also provides intermediates I, II and III.

[0075] The structure of compound I is as follows:

[0076] Among them, R 11 R 21 R 31 and R 51 They can be the same or different, and are independently selected from chloroacetyl, acetyl, benzoyl, pivaloyl, benzyl, and p-methoxybenzyl. Preferably, R 11 R 21 R 31 and R 51 All are benzyl groups.

[0077] The structure of compound II is as follows:

[0078] Among them, R 11 R 21 R 31 and R 51 They may be the same or different, and are independently selected from chloroacetyl, acetyl, benzoyl, pivaloyl, benzyl, and p-methoxybenzyl, with Y selected from H and Na. + K + Li + NH4 + R is preferred 11 R 21 R 31 and R 51 All are benzyl groups, and Y is H or Na. + .

[0079] The structure of compound III is as follows:

[0080] Where Y is selected from H and Na + K + Li+ NH4 + Preferably, Y is H or Na. + .

[0081] Intermediates I, II, and III are generated from trisaccharide intermediate 1 through sequential dehydroxylation, sulfonation, and azide reduction, as shown in the following reaction formulas:

[0082] The dehydroxyl protecting group, sulfonation, and azide reduction can all be carried out using reaction methods and conditions known in the art. In one embodiment of the invention, intermediate 1, under alkaline conditions, simultaneously removes R. 41 R 61 Intermediate I is obtained by reacting methyl ester with SO3·NMe3. In one embodiment of the invention, intermediate I is subjected to SO3·NMe3 to obtain O-sulfonated intermediate II. In one embodiment of the invention, intermediate II undergoes catalytic hydrogenation to remove the benzyl and Cbz groups, while simultaneously reducing the azide to generate an amino group, yielding intermediate III. In one embodiment of the invention, the amino group in compound III is sulfonated under SO3·Py to obtain compound CV010, which is then ion-exchanged using a sodium-type ion exchange resin to obtain compound CV016. The sodium ion exchange resin can be a resin known in the art, including but not limited to Amberlite IR120 Na. + Dowex-50-WX4-Na + wait.

[0083] A fully protected trisaccharide intermediate 2 has the following structural formula:

[0084] Among them, R 11 R 21 R 31 and R 51 They may be the same or different, and are independently selected from chloroacetyl, acetyl, benzoyl, pivaloyl, benzyl, and p-methoxybenzyl. In one specific embodiment of the invention, R 21 R 31 and R 51 All are benzyl, R 11 and R on D sugar 41 For acetyl, R 61 and R on β sugar 41 It is benzoyl.

[0085] The intermediates 2-I, 2-II, and 2-III have the following structures, and are respectively generated from the trisaccharide intermediate 2 through sequential dehydroxylation, sulfonation, and reduction, as shown in the following reaction formulas, wherein the definitions of each group are as described above:

[0086] The dehydroxyl protecting group, sulfonation, and reduction can all be carried out using reaction methods and conditions known in the art. In one embodiment of the invention, intermediate 2, under alkaline conditions, simultaneously removes R. 11 R 41 R 61 Intermediate 2-I is obtained by reacting methyl ester with SO3·NMe3. In one embodiment of the invention, intermediate 2-I is subjected to SO3·NMe3 to obtain O-sulfonated intermediate 2-II. In one embodiment of the invention, intermediate 2-II is subjected to catalytic hydrogenation to remove the benzyl group and Cbz, yielding intermediate 2-III. In one embodiment of the invention, the amino group in compound 2-III is sulfonated under the action of SO3·Py to obtain compound TSC, which is then ion-exchanged with a sodium-type ion exchange resin to obtain compound TSC19. The sodium ion exchange resin may be a resin known in the art, including but not limited to Amberlite IR120 Na. + Dowex-50-WX4-Na + wait.

[0087] The pentasaccharide compound of formula M and its salts in this invention can be prepared by referring to the method in Chinese Invention Patent ZL202111544675.9. Those skilled in the art will know that the synthesized pentasaccharide compound of formula M can be used to prepare the corresponding salts by means of ion exchange resins, etc.; other salts can be prepared by treating the sodium or potassium salts of the prepared pentasaccharide compound of formula M by means of, for example, ion exchange resins.

[0088] The method for synthesizing fondaparinux sodium in this invention is a publicly disclosed method.

[0089] Pharmaceutical composition:

[0090] The present invention also provides a pharmaceutical composition for treating or preventing Alzheimer's disease (AD), comprising an HPA inhibitor. In some embodiments of the present invention, the HPA inhibitor is selected from compounds of formula A or salts thereof or solvates thereof, compounds of formula M or salts thereof or solvates thereof, and fondaparinux sodium.

[0091] The pharmaceutical composition optionally further comprises one or more pharmaceutically acceptable carriers. The pharmaceutically acceptable carriers are various excipients commonly used or known in the pharmaceutical industry, including but not limited to: diluents, binders, antioxidants, pH adjusters, preservatives, lubricants, disintegrants, etc.

[0092] The dosage form of the pharmaceutical composition may be an oral dosage form, such as tablets, capsules, pills, powders, granules, suspensions, syrups, etc.; or an injectable dosage form, such as an injection solution, powder for injection, etc., administered via intravenous, intraperitoneal, subcutaneous, or intramuscular routes. All dosage forms used are well known to those skilled in the art of pharmaceutical science. For example, the pharmaceutical composition may be an injection solution, where the concentration of compound A or its salt or solvation in the injection solution is calculated based on compound A, the concentration of compound M or its salt or solvation in the injection solution is calculated based on compound M, and fondaparinux sodium may be 1-15 mg / ml, such as 5 mg / ml, 10 mg / ml, 12.5 mg / ml, etc.

[0093] The pharmaceutical composition may be administered in combination with other drugs for the treatment or prevention of Alzheimer's disease (AD), or formulated as a combination drug, or may further contain other drugs for the treatment or prevention of AD.

[0094] This invention also provides a method for treating or preventing Alzheimer's disease (AD), characterized in that a therapeutically effective amount of an HPA inhibitor is administered to a patient in need. According to this invention, the HPA inhibitor is selected from compounds of formula A or their salts or solvates, compounds of formula M or their salts or solvates, and fondaparinux sodium.

[0095] This invention also provides the use of HPA inhibitors for the treatment or prevention of Alzheimer's disease (AD). According to this invention, the HPA inhibitor is selected from compounds of formula A or their salts or solvates, compounds of formula M or their salts or solvates, and fondaparinux sodium.

[0096] This invention also provides the use of HPA inhibitors for the treatment or prevention of Alzheimer's disease (AD). According to the invention, the HPA inhibitor is selected from compounds of formula A or their salts or solvates, compounds of formula M or their salts or solvates, and fondaparinux sodium.

[0097] In some embodiments of the above technical solutions of the present invention, the HPA inhibitor is a compound of formula A or its salt or its solvate.

[0098] In some embodiments of the above technical solutions of the present invention, the HPA inhibitor is a compound of formula M or its salt or its solvate.

[0099] In some embodiments of the above technical solutions of the present invention, the HPA inhibitor is fondaparinux sodium.

[0100] Other medications for treating or preventing Alzheimer's disease include, but are not limited to: cholinesterase inhibitors (such as donepezil, rivastigmine, galantamine) and NMDA receptor antagonists (such as memantine), and other adjunctive therapies include, but are not limited to, antioxidants, anti-inflammatory drugs, and medications for mood and behavioral symptoms.

[0101] definition:

[0102] "And / or" will be considered as a specific disclosure of each of the two specified features or components having or not having the other. Therefore, the term "and / or" as used in phrases such as "A and / or B" is intended to include "A and B", "A or B", "A" (alone), and "B" (alone). Similarly, the term "and / or" as used in phrases such as "A, B, and / or C" is intended to cover each of the following: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0103] "Comprising" and "including" have the same meaning and are intended to be open and allow, but do not require, the inclusion of additional elements or steps. When the terms "comprising" or "including" are used herein, the terms "consisting of" and / or "substantially consisting of" are also included and disclosed. Attached Figure Description

[0104] Figure 1. Results of CV122 and CV016 on the improvement of Morris water maze behavior in AD model mice. The left figure is a statistical graph of the average escape latency of mice, and the right figure is a statistical graph of the proportion of time spent in the target quadrant to the total time.

[0105] Figure 2. Statistical graph showing the improvement of spontaneous alternation rate, a behavioral evaluation index of AD model mice, by CV122 and CV016.

[0106] Figure 3 shows the results of CV122 and CV016 improving the behavior of AD model mice in the open field experiment. The left figure is a statistical graph of the percentage of time spent in the central region of the mice, and the right figure is a statistical graph of the activity level of the mice.

[0107] Figure 4. Statistical graph showing the improvement of CV122 and CV016 in the elevated cruciate maze behavioral evaluation index—percentage of open arm entry times—in AD model mice.

[0108] Figure 5. Statistical graph showing the improvement of fall latency in accelerated mode as a behavioral evaluation index of rotarod fatigue experiment in AD model mice by CV122 and CV016.

[0109] Figure 6. Statistical graph of weight changes in mice in the Control group, Model group and Treatment group during the experiment.

[0110] Figure 7. WB results of brain lysis toxic protein Aβ and phosphorylated Tau content in mice in the Control group, Model group and Treatment group.

[0111] Figure 8. Immunohistochemical analysis of HPA expression in brain tissue sections from mice in the Control, Model, and Treatment groups.

[0112] Figure 9. Immunofluorescence analysis of WGA expression in brain tissue sections from mice in the Control, Model, and Treatment groups.

[0113] Figure 10. HPA expression results at the cellular level in the Control group, LPS group, and CV016 group.

[0114] Figure 11. Results of CV016 inhibiting HPA activity in vitro. Detailed Implementation

[0115] The technical solution of the present invention will be further described in detail below with reference to specific embodiments. It should be understood that the following embodiments are merely illustrative and explanatory of the present invention, and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are covered within the scope of protection intended by the present invention.

[0116] Unless otherwise stated, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods. Ac: Acetyl; AgOTf: Silver trifluoromethanesulfonate; Bn: Benzyl; Bz: Benzoyl; ClAc: Monochloroacetyl; CSA: Camphorsulfonic acid; Cbz: Benzyloxycarbonyl; CsF: Cesium fluoride; DBU: 1,8-diazabicycloundec-7-ene; DCM: Dichloromethane; DDQ: 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone; DMF: N,N-dimethylformamide; PMB: p-methoxybenzyl; TfOH: Trifluoromethanesulfonic acid; TBSOTf: tert-butyldimethylsilyltrifluoromethanesulfonate; TEMPO: 2,2,6,6-tetramethylpiperidine oxide; TMSOTf: Trimethylsilyltrifluoromethanesulfonate; Tol: Toluene.

[0117] CV010 and CV016 were prepared according to the methods described in Examples 1-3 of CN116854752A.

[0118] Example 1: Preparation of trisaccharide intermediate III-1

[0119] 1. Preparation method of monosaccharide intermediate 3-1

[0120] Intermediate 9 was obtained by reacting glucosamine hydrochloride 8 with benzyloxyformyl chloride; 1,6-cyclic intermediate 10 was obtained through a two-step reaction; catalytic hydrogenation and azo transfer reaction were used to obtain a common intermediate 11 with an azido group protected at the 2-position; the hydroxyl groups at the 3- and 4-positions were fully benzylated under the action of benzyl bromide and sodium hydride to obtain intermediate 12; 1,6-cyclic intermediate 13 was obtained under the action of acetic anhydride and TBSOTf; the terminal acetyl group was removed under the action of benzylamine to obtain intermediate 14; finally, trichloroacetylimine ester donor 3-1 was obtained under the action of potassium carbonate and trichloroacetonitrile.

[0121] The reaction conditions for each step are as follows: a) Cb2Cl, NaOH, H2O; b) 1) TsCl, Py, MS, 2) EtOH, DBU, NaI; c) 1) 4atm H2, Pd / C, MeOH, 2) TfN3, CuSO4, Et3N, MeOH; d) BnBr, NaH, DMF, 0℃; e) Ac2O, TBSOTf; f) BnNH2, DCM; g) Cl3CCN, K2CO3, DCM, rt.

[0122] 2. Preparation method of fully protected trisaccharide intermediate 1-1

[0123] The synthesized monosaccharide intermediate 3-1, in its mixed configuration, can be used directly in the next reaction without separation. Trichloroacetylimine ester is a relatively common glycosyl donor, typically reacting under mild conditions with high yields. Monosaccharide intermediate 3-1 is glycosylated and coupled with disaccharide intermediate 4-1 synthesized according to known literature methods, yielding a fully protected trisaccharide 1-1 in the presence of trifluoromethanesulfonic acid.

[0124] Monosaccharide intermediate 3-1 and glycosyl acceptor disaccharide intermediate 4-1 were dissolved in redistilled DCM and then added to a solution containing pre-activated DCM. In a reaction flask containing molecular sieves, the mixture was continuously stirred at room temperature for 30 minutes to equilibrate the reaction. After the reaction system temperature was lowered to -20℃, trifluoromethanesulfonic acid was slowly added dropwise. The reaction was monitored by TLC. After the reaction was complete, the molecular sieves were removed by silica gel filtration. The resulting filtrate was concentrated and purified by direct silica gel column chromatography (PE / EA = 5:1) to obtain the fully protected trisaccharide intermediate 1-1.

[0125] 1H NMR(400MHz,CDCl3)δ8.08(d,J=7.6Hz,2H),7.41–7.25(m,22H),7.21–7.18(m,6H),5.46(d,J=3.1Hz,1H),5.14(t,J=3.6Hz,1H),5.02(d,J=2.2Hz,2H),4.88(s,1H),4.85(d,J=3.0Hz,2H),4.82(d,J=5.3Hz,2H),4.77(d,J=4.2Hz,1H),4.74(d,J=3.8Hz,1H),4.64(d,J=3.8Hz,1H),4.58(d,J=10.4Hz,1H),4.54(d,J=10.9Hz,1H),4.32(d,J=2.7Hz,1H),4.30(d,J=2.2Hz,3H),4.24(d,J=3.6Hz,1H),4.21(d,J=3.9Hz,1H),4.14(t,J=4.3Hz,1H),4.02(t,J=4.0Hz,1H),3.99–3.90(m,2H),3.73(dt,J=9.9Hz,3.2Hz,1H),3.63(d,J=3.8Hz,1H),3.61(d,J=2.8 1H),3.58(s,3H),3.47(t,J=9.4Hz,1H),3.31(s,3H),3.21(dd,J=10.2,3.5Hz,1H).

[0126] 13 C NMR(100MHz,CDCl3)δ170.75,170.52,169.35,165.42,155.81,138.23,137.69,137.58,137.42,136.24,133.37,130.01,129.38,128.74,128.52,128.49,128.44,128.39,128.24,128.17,128.13,128.06,127.96,127.88,127.76,127.35,99.32,98.87,98.50,80.05,79.12,77.29,75.62,75.28,74.98,74.90,74.56,74.44,73.32,70.07,69.33,69.12,68.92,67.00,63.62,62.45,62.33,55.29,54.56,52.10,20.87.

[0127] HRMS[M+Na] + m / z 1275.46443(calcd for C67 H 72 N4NaO 20 ,1275.4638).

[0128] 3. Preparation method of trisaccharide intermediate III-1

[0129] The fully protected trisaccharide 1-1 was subjected to the combined action of LiOH, H2O2 and NaOH to simultaneously remove Ac, Bz and methyl ester to obtain trihydroxy compound I-1; heating under the action of SO3·NMe3 gave the intermediate compound II-1 after O-sulfonation; benzyl and Cbz were removed by catalytic hydrogenation, and the azide was reduced to generate an amino group to obtain diamino compound III-1.

[0130] The fully protected trisaccharide compound 1-1 was dissolved in tetrahydrofuran, and then 1.25N LiOH solution and 30% H2O2 solution were added dropwise at room temperature. After stirring for 12 hours, methanol and 6N NaOH solution were added, and stirring was continued for at least 12 hours. After the reaction was confirmed to be complete by TLC, the pH was adjusted to 2 with 4N hydrochloric acid under ice-water bath conditions. The reaction solution was then extracted three times with DCM and concentrated under reduced pressure, followed by silica gel column chromatography (DCM:MeOH = 15:1) to obtain compound I-1. Under argon protection, intermediate I-1 and SO3·NMe3 were dissolved in anhydrous DMF. The reaction system was heated to 65°C and stirred continuously for at least 12 hours until the reaction was complete. After heating was stopped, the reaction system was allowed to rise naturally to room temperature. The reaction solution was concentrated and purified by Sephadex LH-20 gel column chromatography to obtain intermediate II-1. Intermediate II-1 was dissolved in a mixed solvent of methanol, tert-butanol and water (v / v / v = 2:1:1), palladium on carbon was added, and the mixture was stirred for 24 h under a hydrogen pressure of 4 atm. After filtering with filter paper to remove the palladium on carbon, the reaction solution was concentrated to obtain intermediate III-1.

[0131] 1H NMR(400MHz,D2O)δ5.33(d,J=3.7Hz,1H),5.15(s,1H),4.88(d,J=3.7Hz,1H),4.79(d,J=1.8Hz,1 H),4.32–4.25(m,3H),4.23(d,J=3.1Hz,2H),4.13(d,J=2.1Hz,1H),4.11–4.06(m,2H),3.95(d,J =5.6Hz,1H),3.85(t,J=9.8Hz,2H),3.77(t,J=9.9Hz,1H),3.69(d,J=9.5Hz,1H),3.65(s,1H),3. 47(t,J=9.7Hz,1H),3.35(s,3H),3.26(dd,J=10.7Hz,3.6Hz,1H),3.22(dd,J=10.5Hz,3.7Hz,1H).

[0132] 13 C NMR(100MHz,D2O)δ175.15,98.88,96.32,91.44,76.78,73.00,70.50,70.26, 69.39,69.19,68.94,68.67,67.32,66.61,66.16,62.96,55.32,54.22,54.03.

[0133] HRMS[M–H] - m / z 769.0596 (calcd for C 19 H 33 N2O 24 S3,769.0586).

[0134] Example 2: Preparation of compound CV010

[0135] Intermediate III-1 was dissolved in water, and the pH was adjusted to 9-10 with 4N NaOH solution and maintained. Then, sulfur trioxide pyridine complex was added in batches. The reaction was detected by TLC to be complete. The pH of the neutralized reaction solution was about 7-8. The reaction solution was then concentrated and purified by Sephadex G-25 gel column chromatography to obtain compound CV010.

[0136] 1H NMR(400MHz,D2O)δ5.37(d,J=3.6Hz,1H),5.18(d,J=3.0Hz,1H),4.97(d,J=3.6Hz,1H),4.78 (d,J=2.8Hz,1H),4.33-4.26(m,4H),4.21–4.14(m,2H),4.06(t,J=3.2Hz,1H),3.92(td,J=8. 0Hz,7.5Hz,3.5Hz,2H),3.70(t,J=9.5Hz,1H),3.64(d,J=10.1Hz,1H),3.59(d,J=10.1Hz,1H ),3.52(t,J=9.5Hz,1H),3.37(s,3H),3.35(s,1H),3.22(ddd,J=13.1Hz,10.1Hz,3.6Hz,2H).

[0137] 13 C NMR(100MHz,D2O)δ175.37,99.29,98.32,96.95,76.88,75.94,75.90,70.98, 70.05,69.87,69.24,69.15,68.94,68.56,66.87,66.49,57.92,57.76,55.43.

[0138] HRMS[M–H] - m / z 928.9717 (calcd for C 19 H 33 N2O 30 S5,928.9722).

[0139] Example 3 Preparation of compound CV016

[0140] Compound CV010 was treated with Dowex-50-WX4-Na + The column exchanged the sodium salt, and the sugar-containing component was collected to concentrate the solvent, yielding compound CV016.

[0141] 1H NMR(400MHz,D2O)δ5.35(d,J=3.6Hz,1H),5.16(d,J=3.0Hz,1H),4.95(d,J=3.6Hz,1H),4.75(d,J =2.8Hz,1H),4.27(dq,J=13.0Hz,3.8Hz,2.9Hz,4H),4.19–4.12(m,2H),4.04(t,J=3.2Hz,1H),3.9 0(td,J=8.0Hz,7.5Hz,3.5Hz,2H),3.68(t,J=9.5Hz,1H),3.61(d,J=10.1Hz,1H),3.56(d,J=10.1H z,1H),3.50(t,J=9.5Hz,1H),3.35(s,3H),3.33(s,1H),3.20(ddd,J=13.1Hz,10.1Hz,3.6Hz,2H).

[0142] 13 C NMR(100MHz,D2O)δ174.36,99.23,98.22,96.93,76.84,75.93,75.89,70.96, 70.01,69.84,69.22,69.13,68.91,68.51,66.84,66.46,57.89,57.73,55.40.

[0143] HRMS[M-6Na+5H] - m / z 928.9754 (calcd for C 19 H 33 N2O 30 S5,928.9722).

[0144] TSC19 was prepared according to the methods described in Examples 1-2 of CN119708089A.

[0145] Example 4: Preparation of fully protected trisaccharide intermediate 2

[0146] 1. Preparation of monosaccharide intermediate F-1

[0147] Compound 17 was deacetylated under alkaline conditions of MeOH / K2CO3, followed by the addition of a benzylidene reagent and adjustment to acidity with p-toluenesulfonic acid monohydrate to give intermediate 18. Intermediate 18 was refluxed with dibutyltin oxide in anhydrous methanol, and then cesium fluoride and 4-methoxybenzyl chloride were added to selectively protect the 3-hydroxyl group to give intermediate 19. Compound 19 was reacted with benzyl bromide under neutral silver oxide conditions to give compound 20. Compound 20 was deprotected from the PMB protecting group in the presence of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone to give compound 21. Compound 22 was given by adding triethylamine and acetic anhydride dropwise under DMAP catalysis using dichloromethane as solvent. Compound 22 was dissolved in dichloromethane, and the benzylidene group was removed by adding trifluoroacetic acid to give compound 23. Under ice bath conditions, an equal amount of benzoyl chloride was added to selectively protect the 6-position, and the intermediate was purified. The benzylidene group was then moved to the 4-position under silver oxide conditions to give the monosaccharide compound F-1. The reaction process is as follows:

[0148] a)1)K2CO3,MeOH,25℃-rt;2)Benzaldehyde Dimethylacetal,Toluene-4-sulfonic acid,DMF;b)1)Bu2SnO,MeOH,reflux;2)PMBCl,CsF,DMF,90℃;c)Ag2O,BnBr,DCM;d)DDQ,DC M, H2O; e) Et3N, Ac2O, DMAP, DCM; f) TFA, DCM; g) 1) BzCl, Et3N, THF, 0℃-rt; 2) Ag2O, BnBr, DCM.

[0149] Compound F-1:

[0150] 1H NMR (400MHz, CDCl3) δ8.07-8.01(m,2H),7.62(d,J=7.4Hz,1H),7.46(dd,J=7.8,6.6Hz,5H),7.34-7.25 (m,7H),7.22(dd,J=8.2,6.2Hz,2H),6.94(dd,J=8.2,6.1Hz,2H),5.35(d,J=9.2Hz,1H),4.90(d,J=11. 0Hz,1H),4.65(dd,J=16.7,5.9Hz,2H),4.55(dd,J=11.3,3.1Hz,3H),4.46(dd,J=12.0,5.4Hz,1H),3.7 2(ddd,J=9.6,5.3,2.0Hz,1H),3.60(d,J=9.5Hz,1H),3.45(d,J=9.4Hz,1H),2.27(s,3H),1.87(s,3H).

[0151] 13 C NMR (100MHz, CDCl3) δ169.79,166.09,138.09,137.80,137.18,133.17,129.95,129.84,129.70,128.94,128.58,128.48,12 8.44,128.33,128.13,128.09,127.91,87.47,78.74,77.41,77.09,76.91,76.77,76.26,74.76,74.59,63.50,21.18,21.02.

[0152] 2. Preparation method of fully protected trisaccharide intermediate 2

[0153] The synthesized monosaccharide intermediate F-1 was glycosylated and coupled with the disaccharide intermediate 4-1 synthesized according to the method in the known literature, and a fully protected trisaccharide 2 was generated under the action of trimethylsilyl ester.

[0154] Donor F-1 and acceptor 4-1 were dissolved in redistilled dichloromethane and slowly injected into the reaction flask using a syringe. Stirring was initiated, and the mixture was allowed to equilibrate for 40 minutes. Anhydrous ethanol and liquid nitrogen were poured into a Dewar flask and adjusted to -40°C. The reaction flask was then cooled. After 15 minutes, N-iodosuccinimide was added, followed by the addition of a catalyst-level amount of trimethylsilyl trifluoromethanesulfonate via a microsyringe. The mixture was continuously cooled, and after 1 hour, the reaction was complete via TLC. Triethylamine was added to quench the reaction, and the argon gas was shut off for post-processing. The mixture was filtered through a funnel containing a section of silica gel, washed repeatedly with ethyl acetate, concentrated, and purified by column chromatography to obtain the fully protected trisaccharide compound 2.

[0155] 1H NMR (400MHz, CDCl3) δ8.06-7.94(m,4H),7.59-7.33(m,7H),7.29(m,6H),7.25-7.19(m,11H),7.17-7.08(m,5H),7.08-7 .03(m,2H),5.56-5.44(m,2H),5.21(t,J=5.3Hz,1H),5.04(m,2H),4.85-4.71(m,3H),4.64(s,3H),4.60-4.51(m,4H),4. 44(dd,J=12.2,3.5Hz,1H),4.38(d,J=12.4Hz,1H),4.31(dd,J=12.3,3.6Hz,1H),4.23(m,2H),4.18-4.06(m,3H),4.02- 3.89(m,2H),3.72-3.62(m,4H),3.62-3.52(m,2H),3.38(dd,J=10.1,3.5Hz,1H),3.26(s,3H),2.10(s,3H),1.89(s,3H).

[0156] 13 C NMR (100MHz, CDCl3) δ170.95,169.98,169.67,166.19,165.67,155.89,138.49,137.90,137.72,137.60,136. 40,133.25,130.18,129.96,129.72,129.27,128.58,128.53,128.43,128.30,128.26,128.23,128.01,127.97 ,127.85,127.60,127.52,127.40,98.92,98.70,98.43,78.49,77.36,76.56,76.41,76.26,75.52,74.51,74.41,73.52,73.22,72.69,71.12,70.99,69.80,68.99,66.98,63.11,62.22,55.33,54.44,52.34,21.14,20.95.

[0157] Example 5: Preparation of compound TSC19

[0158] Deprotection

[0159] The fully protected trisaccharide 2 was dissolved in an appropriate amount of tetrahydrofuran, and 1.25N LiOH solution and 30% H2O2 solution were added. The reaction flask was fixed on a stirrer, and after 12 hours, anhydrous methanol and 4N NaOH solution were added, and the reaction was continued for another 12 hours. After observing the formation of a thin and long product spot on the TLC plate, the pH of the reaction solution was adjusted to 5–6 with 6N HCl. Extraction was performed using a DCM and saturated NaCl solution system, and the organic phase was collected, dried over anhydrous sodium sulfate, filtered, and evaporated to dryness. Column chromatography was used for separation (DCM:MeOH = 15:1 → 10:1) to obtain the deprotected compound.

[0160] Oxysulfonation

[0161] Weigh out 20 equivalents of SO3·NMe3 for every hydroxyl group and add it to the flask. Seal the flask tightly. Dissolve the deprotected trisaccharide compound in a small amount of anhydrous DMF. Add the solution dropwise to the reaction flask using a syringe. Stir the reaction continuously at 60°C for 36 hours, then evaporate the solvent. Redissolve the oily substance in methanol and perform column chromatography using a Sephadex LH-20 gel column with a 1:1 (v / v) mixture of dichloromethane and methanol as the eluent. Collect the sugar-containing fraction, evaporate the solvent, and elute with methanol using a Dowex-50-WX4-Na gel column. + The column is used to exchange the sugar components for sodium salts, and the sugar-containing components are collected and concentrated to obtain oxysulfonated compounds.

[0162] Hydrogenation and nitrogen sulfonation

[0163] The oxysulfonated compound was dissolved in methanol, and an equal volume of H2O was added. Palladium on carbon was then weighed and placed in a reaction flask. After reacting for 24 hours in a hydrogen atmosphere at 4 atm, the palladium on carbon was filtered off using an organic phase filter membrane. The solution was colorless. The filtrate was evaporated to dryness, and NMR showed no peaks in the aromatic region, indicating that the next step could proceed. The hydrogenated product was dissolved in H2O, and 2N NaOH solution was added to adjust the pH of the reaction solution to 9–10. SO3·Py was weighed and divided into four equal portions, which were added to the reaction solution at 30-minute intervals. After the addition was complete, the mixture was stirred at room temperature for 4 hours. Throughout the addition and reaction, the pH of the reaction solution was constantly monitored to maintain it between 9 and 10. After the reaction time was reached, the pH was neutralized to 7–8 with hydrochloric acid, followed by Sephadex G-25 gel column chromatography using H2O as the eluent. The sugar-containing fraction was collected, and then further chromatography was performed using Dowex-50-WX4-Na2O as the eluent. + The column was exchanged to exchange it for sodium salt, the sugar-containing component was collected, the solvent was concentrated, and the final compound TSC19 was obtained.

[0164] 1H NMR(400MHz,D2O)δ5.26(d,J=3.8Hz,1H),5.17(s,1H),5.01(d,J=3.5Hz,1H),4.43(t,J=9.7Hz,1H),4.33(m,3H),4.27(s,1H),4.21-4.18(m, 1H),4.16-4.12(m,1H),3.99(m,3H),3.82-3.75(m,1H),3.73(d,J=9.6Hz,1H),3.71-3.62(m,3H),3.41(s,3H),3.27(dd,J=10.2,3.6Hz,1H).

[0165] 13 C NMR(100MHz,D2O)δ174.96,99.21,98.13,94.97,81.69,77.15,74.21,72.02, 69.89,69.79,69.64,68.45,68.13,67.40,66.76,66.20,65.18,57.73,55.32.

[0166] Example 6: Therapeutic effect of the compound of the present invention in an AD mouse model

[0167] 1.1 Construction of the mouse AD model and Morris water maze test procedure:

[0168] D-galactose (D-gal) solution: Add 1.2g of D-galactose to 50mL of PBS to achieve a concentration of 24mg / mL;

[0169] Aluminum chloride (AlCl3) solution: Add 200 mg of aluminum chloride to 50 mL of PBS to achieve a concentration of 4 mg / mL;

[0170] Subcutaneous injection of D-galactose solution: 100 μL of D-galactose solution was injected subcutaneously into each mouse for 60 days;

[0171] Intraperitoneal injection of aluminum chloride solution: 100 μL of aluminum chloride solution was injected into each mouse intraperitoneally for 60 days.

[0172] Starting 30 days after the injection of D-gal and AlCl3, the Model group was given PBS, while the treatment group was given subcutaneous injections of CV016 (20 mg / kg) and CV122 (20 mg / kg), respectively, for 60 consecutive days.

[0173] Morris water maze behavioral test was performed on the control group (normal mice, which were given the same volume of PBS at all equivalent time points), the model group, the CV016 group, and the CV122 group.

[0174] After drug administration, mice underwent the Morris water maze behavioral test. The experiment used a circular pool with a diameter of 120 cm, with the water temperature controlled at 22±1℃. The water surface was covered with white powder to conceal a 10 cm diameter platform (fourth quadrant). Movement trajectories were recorded using a video system. The experimental procedure included four days of orientation and navigation training (once daily, recording escape latency) and a fifth day of spatial exploration (after removing the platform, recording the percentage of time spent in the target quadrant and the number of times the platform was traversed). Data were automatically analyzed to determine the average escape latency, spatial preference index, and path efficiency, and then manually reviewed to remove outliers.

[0175] The results of the Morris water maze behavioral assessment are shown in Figure 1. The assessment revealed that the treated mice (CV016 and CV122 groups) exhibited significant cognitive improvements, as well as enhanced learning and memory abilities, compared to the Alzheimer's disease model group (Model group). Specifically, the mean escape latency (EL) was 10.2 seconds in the Control group, extended to 37.2 seconds in the Model group, decreased to 22.8 seconds in the CV016 group, and decreased to 21.4 seconds in the CV122 group, indicating improved cognition in the treated groups. The Control group spent 44.9% of its total time in the target quadrant, while the Model group spent only 18.0%. However, the percentages in the CV122 group and CV016 group recovered to 37.2% and 39.4% respectively, all significantly different from the Model group, indicating a significant improvement in learning and memory abilities in the treated groups.

[0176] 1.2 Mouse Y-maze Experiment Procedure:

[0177] The experiment used a classic Y-shaped maze apparatus (arm length 40cm, angle 120°). Mice were acclimatized for 3 days prior to the experiment (5 minutes of free exploration daily). After drug administration, mice were placed in the center of the maze, and the number and order of entry into each arm within 5 minutes were recorded. The spontaneous alternation rate was calculated as (actual alternation count / (total arm entry count - 2) × 100%). The total number of entries, average speed, and number of errors (continuous entry into the same arm or repeated entry into an already visited arm) were monitored simultaneously. The experimental environment was controlled at 22±1℃ with no other noise. The system automatically analyzed the trajectory data, and abnormal behaviors were manually verified.

[0178] The behavioral assessment results of the Y-maze are shown in Figure 2. Analysis showed that the spontaneous alternation rate in the Model group was significantly lower than that in the Control group (48.2% vs. 70.6%, p<0.01), with a decrease in total entry attempts and an increase in the number of errors, indicating significant spatial working memory impairment in the AD model mice. The spontaneous alternation rate in the treatment groups (69.0% in the CV122 group and 67.5% in the CV016 group) was significantly higher than that in the Model group. The total entry attempts in the treatment groups were also significantly improved compared to the Model group, with a decrease in the number of errors.

[0179] 1.3 Procedure for the mouse open field experiment:

[0180] The experiment used a standardized open-field apparatus (a 40cm×40cm×30cm black box divided into a central area and a peripheral area), with the environment controlled at 22±1℃. A camera was installed on top to record the movement trajectory. Mice were allowed 3 days of environmental acclimatization (5 minutes of free exploration each day) before the experiment. During the formal test, the mice were placed in the central area, and their movement was recorded within 10 minutes.

[0181] Total distance traveled (cm): reflects the level of spontaneous activity and activity level;

[0182] Percentage of time spent in the central area (%): assessing anxiety-like behaviors.

[0183] The behavioral assessment results of the open field experiment are shown in Figure 3. Analysis showed that the total distance traveled by mice in the Model group (1366.4 mm) was significantly lower than that in the Control group (3676.0 mm), and the percentage of time spent in the central region (1.1%) was also significantly different from that in the Control group (4.7%). Furthermore, the activity level was significantly lower in the Model group (8.4 vs. 12.7%), indicating a significant reduction in activity and anxiety-like behavior in the AD model mice. The total distance traveled by mice in the CV122 and CV016 groups (2407.2 mm, 2745.8 mm vs. 1366.4 mm) and the percentage of time spent in the central region (4.0%, 4.5% vs. 1.1%) were significantly improved compared to the Model group, and their activity levels were also significantly improved (10.8, 11.1 vs. 8.4).

[0184] 1.4 Procedure for the elevated cruciate maze experiment in mice:

[0185] The experiment used a standard elevated cross maze setup (arm length 50cm, open arms without sidewalls, closed arms with a 15cm high black baffle, maze 50cm above the ground), with the environment controlled at 22±1℃. A camera was installed at the top to record the movement trajectory. Mice were allowed 3 days of environmental acclimatization (5 minutes of free exploration each day) before the experiment. During the formal test, mice were placed in the central area of ​​the maze (facing the open arms), and the percentage of times they entered the open arms within 5 minutes was recorded, which represents the core indicator of anxiety level.

[0186] The behavioral assessment results of the elevated cruciate maze are shown in Figure 4. Analysis showed that the percentage of open arm entry attempts in the Model group (24.4%) was 50% lower than that in the Control group (51.4%), indicating significant anxiety-like behavior in the AD model mice. The percentage of open arm entry attempts in the treatment groups was significantly improved compared to the Model group, with the CV122 group showing a percentage of 48.7% and the CV016 group showing a percentage of 51.5%.

[0187] 1.5 Procedure for mouse rotarod fatigue experiment:

[0188] The experiment used a multi-channel rotarod apparatus (3 cm in diameter, rotation speed range 0-30 rpm / min) at an environmental temperature of 22±1℃. The test conditions were set to accelerated mode: linear increments from 0-30 rpm for 200 seconds, with a total duration of 5 minutes. The fall latency (s) of the mice in accelerated mode was recorded during the test. Data were automatically analyzed and then manually verified to ensure the reliability of the experimental results.

[0189] The behavioral rating results of the rotarod fatigue test are shown in Figure 5. Analysis showed that the fall latency in the Model group (95.0 s) was significantly shorter than that in the Control group (256.1 s, p < 0.01), indicating impaired motor coordination in the AD model mice. The fall latency in the treatment groups was significantly improved compared to the Model group (p < 0.05), with the CV122 group having a latency of 232.7 s and the CV016 group having a latency of 240.2 s.

[0190] 1.6 Mouse weight record

[0191] From the start of modeling, the weight changes of mice were recorded once a week for a total of 90 days.

[0192] The results showed that the body weight of mice in the Control group increased continuously, while the body weight of mice in the Model group was unstable and generally showed a downward trend. Specifically, the body weight decreased from 0 to 49 days (slowly from 0 to 42 days, and significantly from 42 to 49 days), the body weight of mice in the Model group increased slowly from 49 to 77 days, and then slightly rebounded after decreasing from 77 to 90 days. The body weight of mice in the treatment groups (CV122 and CV016 groups) showed a significant upward trend.

[0193] 1.7 Detection of toxic protein Aβ and phosphorylated Tau levels in mouse brain tissue

[0194] Western blot analysis of mouse brain lysate for the detection of toxic proteins Aβ and phosphorylated Tau: Fresh brain tissue from mice (n=6 / group) was collected and homogenized with RIPA lysis buffer containing a protease inhibitor (PMSF) (500 μL / 100 mg tissue). The homogenate was centrifuged at 12,000 × g for 30 minutes at 4°C. The supernatant was used for protein quantification using the BCA method. 30 μg of total protein was separated by 10% SDS-PAGE gel electrophoresis and transferred to a PVDF membrane (200 mA constant current for 60 minutes). After blocking with 5% skim milk powder for 1 hour, the following antibodies were added: anti-Aβ antibody (1:1000, Affinity); anti-phosphorylated Tau antibody (p-Tau Thr181, 1:1000, Affinity); and GAPDH internal control antibody (1:5000, Sigma). Incubation was performed overnight at 4°C. The next day, the membrane was washed with TBST, and secondary antibody (1:5000) was added and incubated at room temperature for 1 hour. Chemiluminescence imaging was then performed.

[0195] The Western blot results are shown in Figure 7. The results showed that the expression levels of Aβ protein and phosphorylated Tau (p-Tau Thr181) were significantly higher in the Model group than in the Control group, while the Aβ levels and phosphorylated Tau were lower in the treatment groups (CV122 group and CV016 group) than in the Model group. The GAPDH internal control showed good homogeneity.

[0196] 1.8 Immunohistochemical analysis of HPA expression and immunofluorescence analysis of WGA expression were performed on mouse brain tissue.

[0197] Paraffin sections of mouse brains were pretreated as follows:

[0198] 1. Baking: Place the slices on a stainless steel slicing rack and bake in a 60℃ constant temperature oven for 4 hours;

[0199] 2. Dewaxing to water: Place the paraffin tissue sections in xylene I for 10 min; xylene II for 10 min; anhydrous ethanol I for 5 min; anhydrous ethanol II for 5 min; 95% ethanol for 5 min; 80% ethanol for 5 min; 70% ethanol for 5 min; distilled water for 3 min;

[0200] 3. Antigen retrieval: Place 1×citric acid antigen retrieval solution in a beaker, microwave on high, and once boiling, add the slides. Microwave on medium heat for 8 minutes, maintaining a gentle simmer, avoiding boiling. Cool for 7 minutes, then microwave on low for 7 minutes. Allow to stand at room temperature. After cooling to room temperature, wash three times with distilled water, 5 minutes each time.

[0201] 4. Inactivation of endogenous catalase: Immerse the slices in 3% H2O2 for 10 min to inactivate endogenous catalase, and wash with distilled water 3 times, 5 min each time;

[0202] 5. Antigen blocking: Blot dry the slide with absorbent paper, mark the tissue area with an immunohistochemical pen, add 10% goat serum and block for 30 minutes to reduce background staining.

[0203] Subsequently, immunohistochemistry was performed on a portion of the slides to analyze the expression of HPA in the cerebral cortex and hippocampus of mice from different groups. The specific steps are as follows:

[0204] 6. Add primary antibody (HPA polyclonal antibody): Remove excess liquid, place the slide in a humidified chamber, add primary antibody (1:200), and incubate overnight at 4°C.

[0205] 7. Add secondary antibody (peroxidase-anti-rabbit IgG): After drying the humidified chamber at room temperature for 15 min, wash three times with PBST for 5 min each time. Add the secondary antibody working solution, incubate at 37℃ for 30 min, and wash three times with PBS for 5 min each time.

[0206] 8. DAB staining: Add 50 μL of DAB concentrate to each 1 mL of DAB substrate solution, mix well to prepare the DAB working solution. Add 50 μL of DAB working solution to the section, incubate at room temperature, and observe the staining under a microscope. After staining, rinse with tap water to stop the staining.

[0207] 9. Nuclear counterstaining: Add hematoxylin staining solution for 3 min, rinse with tap water, differentiate with differentiation solution for 30 s, and rinse with tap water;

[0208] 10. Dehydration, clearing, mounting, and microscopic examination: The slides are sequentially subjected to 70%, 80%, 95%, and 100% alcohol for 2 minutes each, and xylene I and II for 3 minutes each. After removal, the slides are air-dried and mounted with neutral resin. The images are then observed and analyzed under an optical microscope.

[0209] Immunohistochemical results are shown in Figure 8: HPA expression in the cerebral cortex and hippocampus of the Model group mice was significantly higher than that in the Control group, while HPA expression in the CV016 group mice was significantly lower than that in the Model group.

[0210] Immunofluorescence was performed on another portion of the tissue sections to analyze the expression of WGA in the brain tissue of mice from different groups. The specific steps are as follows:

[0211] 6. Add CD31 primary antibody: Shake off excess liquid, place the slide in a humidified chamber, add CD31 primary antibody (1:200), and incubate overnight at 4°C.

[0212] 7. Add secondary antibody: After drying the humidified chamber at room temperature for 15 minutes, wash three times with PBST for 5 minutes each time. Add goat anti-rabbit secondary antibody working solution, incubate at room temperature for 1 hour, and wash three times with PBS for 5 minutes each time.

[0213] 8. WGA staining: Add WGA-FITC staining solution, incubate at room temperature for 30 min, wash 3 times with PBS, 5 min each time.

[0214] 9. Nuclear staining: Mount the slides with DAPI-containing mounting medium. Observe and analyze the results using a laser confocal fluorescence microscope.

[0215] The immunofluorescence results are shown in Figure 9: the expression of WGA in the brain tissue of the Model group mice was significantly lower than that in the Control group, indicating that the glycocalyx of the vascular epithelial cells in the brain of AD mice was destroyed; the expression of WGA in the brain tissue of the CV016 group mice was higher than that in the Model group, indicating that the destruction of the glycocalyx of the vascular epithelial cells in their brains was alleviated.

[0216] 1.10 Inhibitory activity of CV016 against HPA in BV2 microglia

[0217] 1. Cell preparation: Seed BV2 cells on cell slides and culture overnight.

[0218] 2. LPS induction and administration: Cells were divided into a control group, an LPS group, and a CV016 group. LPS (10 μg / mL) was added to the LPS and CV016 groups. After 4 h, CV016 groups were incubated with CV016 (20 μM) for 24 h.

[0219] 3. Cell fixation: Remove the culture medium and wash the cells three times with PBS for 5 min each time. Add 4% paraformaldehyde fixative and fix at room temperature for 15 min. Wash three times with PBS for 5 min each time.

[0220] 4. Permeabilization: Permeabilize cells with 0.1% Triton X-100 solution, incubate at room temperature for 10 min, and then wash three times with PBS for 5 min each time.

[0221] 5. Blocking: Add 10% goat serum and incubate at room temperature for 30 minutes.

[0222] 6. Primary antibody incubation (HPA polyclonal antibody): Place the cell smear on a glass slide, add the primary antibody (1:200), and incubate overnight at 4°C. After incubation, wash three times with PBS for 5 minutes each time.

[0223] 7. Secondary antibody incubation (goat anti-rabbit secondary antibody): Add the diluted secondary antibody solution and incubate at room temperature in the dark for 1 hour. After incubation, wash three times with PBS for 5 minutes each time.

[0224] 8. Mounting: Mount the slides using mounting medium containing DAPI.

[0225] 9. Fluorescence microscopy observation: Observe the expression of HPA under a fluorescence microscope using the appropriate fluorescence channel.

[0226] The experimental results are shown in Figure 10. The fluorescence intensity of HPA in the LPS group was significantly higher than that in the Control group, indicating that HPA was highly expressed in BV2 cells after LPS stimulation. However, the fluorescence intensity of HPA after CV016 administration was significantly weaker than that in the LPS group, indicating that CV016 can inhibit the high expression of HPA induced by LPS stimulation.

[0227] 1.11 In vitro HPA inhibitory activity of CV016

[0228] Reagent preparation: Active heparanase was diluted to 120 ng / mL with Buffer A, biot-HS-K was diluted to 1.4 ng / mL with Buffer B (pH 5.5), SA-d2 was diluted to 1 g / mL with Buffer C (pH 7.5), and compound samples were diluted to different concentration gradients with Buffer A.

[0229] Experimental Methods: 4 μL of CV016 solution and 3 μL of heparanase solution or Buffer A were added to a micro-96-well plate. After incubating the micro-96-well plate at 37°C for 10 min, the enzyme reaction was initiated by adding 3 μL of biot-HS-K and incubated at 37°C for 30 min. Then, 10 μL of SA-d2 solution or Buffer C was added. After incubation at room temperature for 15 min, the HTRF signal was detected using a microplate reader, with excitation at 384 nm and emission at 620 nm and 665 nm. The average energy transfer rate (ΔF%) for each sample was calculated using the fluorescence intensity ratio at 665 nm / 620 nm. The positive control system consisting of biot-HS-K and SA-d2 should produce the largest ΔF%, while the negative control (biot-HS-K) should produce the smallest ΔF%.

[0230] The experimental results are shown in Figure 11. CV016 showed a significant inhibitory effect on HPA, with an IC50 value of 30.77 μM.

[0231] The embodiments of the present invention have been described above. However, the present invention is not limited to the above embodiments. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.

Claims

1. Use of HPA inhibitors in the preparation of drugs for the treatment or prevention of Alzheimer's disease.

2. HPA inhibitors are used to treat or prevent Alzheimer's disease.

3. HPA inhibitors for the treatment or prevention of Alzheimer's disease.

4. A method for treating or preventing Alzheimer's disease, characterized in that, Administer therapeutically effective doses of HPA inhibitors to patients in need.

5. Use HPA inhibitors to treat or prevent Alzheimer's disease.

6. Use HPA inhibitors when treating or preventing Alzheimer's disease.

7. The use or method as described in any one of claims 1-6, characterized in that, The HPA inhibitor is selected from trisaccharide compounds of formula A or their salts or solvates, pentasaccharide compounds of formula M or their salts or solvates, and fondaparinux sodium; wherein... The structural formula of the trisaccharide compound of formula A is as follows: Among them, R1, R2, R3, and R4 may be the same or different, and are independently selected from H or -SO3H. R5 is a -C1-5 alkyl, -C1-5 alkylene-NH2, or -C1-5 alkylene-NHSO3H. R6 is -OH, -OSO3H or -NHSO3H; The structural formula of the pentasaccharide compound of formula M is as follows: The salt of formula A or formula M is a salt formed with a monovalent cation, a divalent cation, and / or a trivalent cation; Preferably, the monovalent cation is selected from Na. + K + Li + NH4 + The divalent cation is selected from Ca. 2+ Cu 2+ Zn 2+ Fe 2+ Mg 2+ Mn 2+ The trivalent cation is selected from Al. 3+ Fe 3+ .

8. The use or method as described in claim 7, characterized in that, In formula A, R1 is selected from H or -SO3H; R2, R3 and R4 are the same, all of which are H; R6 is -OH, -OSO3H or -NHSO3H.

9. The use or method as described in claim 7, characterized in that, In formula A, R1, R2, R3 and R4 are all H, and R6 is -NHSO3H.

10. The use or method as described in claim 7, characterized in that, In formula A, R1 is -SO3H, R2, R3 and R4 are the same H, and R6 is -OH.

11. The use or method as described in claim 7, characterized in that, In formula A, R5 is -C1-3 alkyl, -C2-4 alkylene-NH2, or -C2-4 alkylene-NHSO3H; Preferably, R5 is methyl, ethyl, -C2H4NH2, -C2H4NHSO3H, -C3H6NH2 or -C3H6NHSO3H.

12. The use or method as described in claim 7, characterized in that, The salt of formula A or formula M is a salt formed with a monovalent cation selected from Na. + K + Li + NH4 + Alternatively, the salt of formula A or formula M is a salt formed with a divalent cation selected from Ca. 2+ Cu 2+ Zn 2+ Fe 2+ Mg 2+ Mn 2+ .

13. The use or method as described in any one of claims 1-6, characterized in that, The HPA inhibitor is selected from compounds with the following structures:

14. The use or method as described in any one of claims 1-6, characterized in that, The HPA inhibitor is selected from compounds with the following structures:

15. The use or method as described in any one of claims 1-14, characterized in that, The prevention or treatment of Alzheimer's disease is to delay the decline of cognitive function in patients, improve the core clinical symptoms of Alzheimer's disease, and / or reduce or inhibit the production and accumulation of toxic protein Aβ and phosphorylated Tau protein; preferably, the core clinical symptoms are selected from memory impairment, cognitive dysfunction, aphasia, apraxia, anxiety, depression, and hallucinations.